Bristol-Myers Squibb Company
NYSE: BMY
$58.73
-$0.14 (-0.2%)
Closing Price on November 25, 2024
BMY Articles
ThinkstockThe trend towards generic drugs is nothing new. It does not matter if a drug has billions of dollars in annual sales or not, when they go off patent generics can enter the market. Now the...
Published:
Tuesday's top analyst upgrades, downgrades and initiations include GE, IBM, Bristol-Myers Squibb, Encana, Halliburton, Rio Tinto and WhiteWave Foods.
Published:
In a new report, Cowen analysts have sights set on three major pharmaceutical stocks that they expect to have rising first-quarter earnings.
Published:
SunTrust Robinson Humphrey analysts expect the pharmaceutical industry to outperform in 2015, driven in part by a solid new product cycle and an attractive five-year growth rate.
Published:
A new research report from the technical team at RBC cites Bristol-Myers Squibb, Eli Lilly, Mylan and Perrigo as stocks that may continue to show sector leadership.
Published:
A new research report from SunTrust Robinson Humphrey is very positive on pharmaceuticals, and the analysts expect the sector to outperform this year.
Published:
Rigel Pharmaceuticals and Bristol-Myers Squibb announced Monday morning that they have entered into a collaboration agreement.
Published:
24/7 Wall St. reviewed the new Credit Suisse Top Picks for 2015 report, and here are five of the top health care picks.
Published:
If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today.
Published:
In a new research report, the SunTrust Robinson Humphrey team highlights the top pharmaceutical stocks to buy for 2015.
Published:
Thursday's top analyst upgrades, downgrades and initiations include Applied Materials, Broadcom, Cisco Systems, Genworth Financial and SanDisk.
Published:
These are the top analyst upgrades and downgrades featured by 24/7 Wall St. for Thursday, October 16, 2014.
Published:
The data is grim: cancer is increasing. Sales of these top oncology drugs are likely to increase as well.
Published:
A new research report from the analysts at Cowen sees a potential wave of biotech deals, some of which could be of the blockbuster variety.
Published:
A new report from the pharmaceutical team at Credit Suisse highlights four top stocks to buy for the remainder of 2014
Published: